Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
Journal article

Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group

  • Stupp, R. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Mason, W. P. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Van Den Bent, M. J. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Weller, M. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Fisher, B. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Taphoorn, M. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Brandes, A. A. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Cairncross, G. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Lacombe, D. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
  • Mirimanoff, R. O. University Hospital (CHUV), Lausanne, Switzerland; Princess Margaret Hospital, Toronto, ON, Canada; University Hospital/Rotterdam Cancer Center, Rotterdam, Netherlands; University of Tübingen Medical School, Tübingen, Germany; University of Western Ontario, London, ON, Canada; University Medical Center, Utrecht, Netherlands; Azienda Ospedale-Università, Ospedale Busonera, Padova, Italy; University of Calgary, Calgary, AB, Canada; EORTC Data Center, Brussels, Belgium
Show more…
Published in:
  • Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2004, vol. 22, no. 14_suppl, p. 2-2
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/293831
Statistics

Document views: 21 File downloads: